The male sexual dysfunction that has the most medical or surgical remedies is erectile dysfunction. The erectile dysfunction has received a disproportionate amount of attention in comparison to other types of sexual dysfunctions, which may be attributable to the success that physicians have experienced in approaching this problem.
Current advances for the management of male erectile dysfunction are increasingly made in the scientific understanding of the neurovascular-endocrinologic effectors and interactions involving the central and peripheral regulatory levels of sexual physiology. These contemporary innovative advances are approaching more effective therapeutic targets and technologies that can facilitate sexual response and behavior as well as sexual organ restoration for the patients with erectile dysfunction. This lecture provides the dramatic evolution history and future perspective as well as the variety of marketed therapeutic options in the field of the management of male erectile dysfunction.
Several studies have investigated the role of psychological processes on the etiology and maintenance of sexual dysfunction. Studies on dispositional factors have supported Barlow’s theory (2002) suggesting as well as infertility treatment are now finding themselves more heavily involved in the decision-making process concerning patients; Neuroticism and low Positive trait-affect are more prevalent in individuals with sexual dysfunction compared to controls (Oliveira & Nobre, in press; Quinta Gomes & Nobre, 2012).
The aim of our study is to evaluate the endothelial response, based on Intima Media Thickness (IMT), in patients with mild and moderate erectile dysfunction after a daily treatment with a natural compound Tradamixina® (Tribulus Terrestris + Alga Ecklonia Bicyclis + Chitosan Oligosaccharide Water Soluble)
The incidence of erectile dysfunction (ED) increases with age and may also be associated with other health problems such as diabetes, obesity, smoking and metabolic syndrome. It is also regarded as
Over the past 20-30 years, the Premature Ejaculation (PE) treatment paradigm, previously limited to behavioural psychotherapy, has expanded to include drug treatment. Animal and human sexual psychopharmacological studies have demonstrated that serotonin and 5-HT receptors are involved in ejaculation and confirm a role for SSRIs in the treatment of PE. Multiple well-controlled evidence-based studies have demonstrated the efficacy and safety of SSRIs in delaying ejaculation, confirming their role as first-line agents for the medical treatment of lifelong and acquired PE. Daily dosing of SSRIs is associated with superior fold increases in IELT compared to on-demand SSRIs.
Nocturnal tumescence (NT ) has long been used as a diagnostic screening tool for a range of issues. Research supports that a lack, or lackluster, of NT is strongly associated with organogenic erectile dysfunction (ED) and weakly associated with psychogenic ED. Nevertheless, the use of self-report, as opposed to objective measurement, of NT is thought to over-estimate the rate of organogenic ED.
Prevalence of erectile dysfunction (ED) reported in the general population range widely. There do not appear to have been studies using well standardised measures of ED in men who have sex with men (MSM) in Australia. The current study investigated the level of ED in an Australian MSM population.
Phosphodiesterase type-5 inhibitors (PDE-5Is) have been successful in assisting men with erectile dysfunction (ED). Research has suggested that these medications are used recreationally in both heterosexual males and men who have sex with men (MSM). The current study was undertaken to assess the impact of ED and other factors on PDE-5I use in an Australian MSM population.
This presentation, "Responding to the needs of consumers with complex trauma histories a consumer perspective" focuses on the needs of adult survivors of child abuse, highlighting the frequent